What is the 13F Pro Quality Score for IMDX?

13F Pro ranks Insight Molecular Diagnostics Inc. (IMDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMDX's current score at https://13fpro.ai/company/IMDX (free sign-up required for the full ranking).

Where does 13F Pro source IMDX data?

All Insight Molecular Diagnostics Inc. fundamentals and ownership data come directly from SEC EDGAR. Insight Molecular Diagnostics Inc. files with the SEC under CIK 1642380. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMDX in?

Insight Molecular Diagnostics Inc. (IMDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMDX research updated on 13F Pro?

IMDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Insight Molecular Diagnostics Inc.(IMDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1642380 IMDX stock profile & AI dashboard →

13F Pro Quality Score

27.6/100

Rank #2,575 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IMDX Scores 28/100

exact factor attribution · 2026-09-11

IMDX's composite is driven by revenue growth and earnings growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.6 pts

78th pct

Earnings growth

+2.2 pts

95th pct

Earnings quality

-0.7 pts

43th pct

Institutional flow

-1.8 pts

14th pct

Shareholder dilution

-2.1 pts

8th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-7.0 pts

4th pct

Free cash flow

-7.0 pts

3th pct

Scale

-7.0 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IMDX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Insight Molecular Diagnostics Inc. (IMDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMDX at 27.6/100 on a 32-signal composite quality model, placing it at rank #2,575 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Insight Molecular Diagnostics Inc. reports quarterly revenue of $239.0K, net income of $-11.3M, free cash flow of $-10.0M. Top institutional holders of IMDX by reported 13-F value include BROADWOOD CAPITAL, AWM Investment Company, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. IMDX trades on the Nasdaq exchange and files with the SEC under CIK 1642380. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Insight Molecular Diagnostics Inc. directly from SEC EDGAR. Insight Molecular Diagnostics Inc.'s 13F Pro composite quality score has ranged between 7 and 28 since 2024, currently 27.6 — an improving long-term trajectory across 10 quarterly and live scoring snapshots.

Revenue

Q2 2026

$239.0K

Net Income

Q2 2026

$-11.3M

Free Cash Flow

Q2 2026

$-10.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+115.6% YoY

$4.1MFY 2025

FY22 $958.0KFY23 $1.5MFY24 $1.9MFY25 $4.1M

Net Income

+17.2% YoY

$-50.2MFY 2025

FY22 $-72.9MFY23 $-27.8MFY24 $-60.7MFY25 $-50.2M

Operating Income

+16.2% YoY

$-51.1MFY 2025

FY22 $-18.0MFY23 $-25.1MFY24 $-61.0MFY25 $-51.1M

EPS (Diluted)

+64.6% YoY

$-1.65FY 2025

FY22 $-13.25FY23 $-3.75FY24 $-4.66FY25 $-1.65

Total Assets

-26.6% YoY

$25.8MFY 2025

FY22 $100.1MFY23 $74.9MFY24 $35.1MFY25 $25.8M

Op. Cash Flow

-7.2% YoY

$-22.2MFY 2025

FY22 $-45.6MFY23 $-23.3MFY24 $-20.7MFY25 $-22.2M

Free Cash Flow

-19.6% YoY

$-25.4MFY 2025

FY22 $-49.9MFY23 $-23.6MFY24 $-21.2MFY25 $-25.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.1M +115.6%	$1.9M +25.1%	$1.5M +56.9%	$958.0K -56.4%	$2.2M +80.8%	$1.2M
Net Income	$-50.2M +17.2%	$-60.7M -118.4%	$-27.8M +61.9%	$-72.9M -13.7%	$-64.1M -114.1%	$-29.9M
Operating Income	$-51.1M +16.2%	$-61.0M -142.8%	$-25.1M -39.7%	$-18.0M +66.5%	$-53.7M -80.8%	$-29.7M
EPS (Diluted)	$-1.65 +64.6%	$-4.66 -24.3%	$-3.75 +71.7%	$-13.25	—	—
Total Assets	$25.8M -26.6%	$35.1M -53.2%	$74.9M -25.2%	$100.1M -37.3%	$159.6M +187.9%	$55.4M
Operating Cash Flow	$-22.2M -7.2%	$-20.7M +11.3%	$-23.3M +48.8%	$-45.6M -26.8%	$-35.9M -38.3%	$-26.0M
Free Cash Flow	$-25.4M -19.6%	$-21.2M +10.2%	$-23.6M +52.7%	$-49.9M -30.7%	$-38.2M -40.4%	$-27.2M

Get alerted when IMDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Insight Molecular Diagnostics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMDX

BROADWOOD CAPITAL INC
$74.8M12,684,884 sh
AWM Investment Company, Inc.
$16.7M2,836,692 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.3M735,847 sh
PURA VIDA INVESTMENTS, LLC
$2.9M484,845 sh
Family Office Research LLC
$2.2M368,849 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.5M256,903 sh
FNY Investment Advisers, LLC
$1.1M182,561 sh
JANE STREET GROUP, LLC
$930.3K157,682 sh
BlackRock, Inc.
$888.1K150,521 sh
VANGUARD FIDUCIARY TRUST CO
$735.0K124,576 sh

Fund	Value	Shares
BROADWOOD CAPITAL INC	$74.8M	12,684,884
AWM Investment Company, Inc.	$16.7M	2,836,692
VANGUARD CAPITAL MANAGEMENT LLC	$4.3M	735,847
PURA VIDA INVESTMENTS, LLC	$2.9M	484,845
Family Office Research LLC	$2.2M	368,849
GEODE CAPITAL MANAGEMENT, LLC	$1.5M	256,903
FNY Investment Advisers, LLC	$1.1M	182,561
JANE STREET GROUP, LLC	$930.3K	157,682
BlackRock, Inc.	$888.1K	150,521
VANGUARD FIDUCIARY TRUST CO	$735.0K	124,576

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMDX on your watchlist

Track score changes the day Insight Molecular Diagnostics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMDX a good stock to buy?

13F Pro's AI-powered analysis of Insight Molecular Diagnostics Inc. (IMDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMDX are available on the IMDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMDX is classified as a small company.

Which hedge funds own IMDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Insight Molecular Diagnostics Inc.'s investment landscape.